Skip to main content
. 2022 Sep 13;12:914385. doi: 10.3389/fonc.2022.914385

Figure 2.

Figure 2

Kaplan–Meier analyses of progression-free survival and overall survival before (A, B) and after (C, D) propensity score matching in patients treated with T+S or T+S+ICIs. T+S, transarterial chemoembolization+sorafenib; T+S+ICIs, transarterial chemoembolization+sorafenib+immune checkpoint inhibitors.